SCHEDULE 13D

CUSIP Number(s):

67577R102

Name of reporting person

Foundation Fighting Blindness Retinal Degeneration Fund

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,792,171.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,792,171.00

Aggregate amount beneficially owned by each reporting person

3,792,171.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.66 %

Type of Reporting Person (See Instructions)

CO, OO

Comment for Type of Reporting Person:

Percent of class represented in Row (11) is based on 81,395,539 shares of common stock, $0.0001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2026.

SCHEDULE 13D

CUSIP Number(s):

67577R102

Name of reporting person

Foundation Fighting Blindness, Inc.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,792,171.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,792,171.00

Aggregate amount beneficially owned by each reporting person

3,792,171.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4.66 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

Percent of class represented in Row (11) is based on 81,395,539 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2026.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.0001 par value per share

(b)

Name of Issuer:

Opus Genetics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

8 Davis Drive, Suite 220, Durham, NORTH CAROLINA , 27713.

Item 1 Comment:

This Amendment No. 3 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024, which was amended on Schedule 13D/A dated March 6, 2025 and December 11, 2025, which relates to the Common Stock of the Issuer, filed by the Reporting Persons. This Amendment No. 3 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of selling shares of the Issuer's Common Stock on May 18, 2026. Upon the closing of this transaction contemplated, the Reporting Persons will cease to be the beneficial owner of more than five percent of the Issuer's Common Stock. Accordingly, the Reporting Persons expect that this will be the final amendment to their Schedule 13D and constitutes an "exit filing" to terminate the Reporting Persons' reporting obligations under Section 13(d) of the Exchange Act upon such closing.

Item 5.

Interest in Securities of the Issuer

(a)

3,792,171 - 4.66%

(b)

3,792,171

(c)

Reference is made to the Form 4 filed by the Reporting Persons on May 20, 2026 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov. The information reported in the filings are expressly incorporated herein.

(e)

Not Applicable.

Item 7.

Material to be Filed as Exhibits.

Exhibit 1 - Agreement and Plan of Merger, dated October 22, 2024, by an among Ocuphire Pharma, Inc., Orange Merger Sub I, Inc., Orange Merger Sub II, LLC, and Opus Genetics Inc. (incorporated by reference to Exhibit 2.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024). Exhibit 2 - Certificate of Designations of the Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024). Exhibit 3 - Form of Lock-Up Agreement (included as Exhibit B to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference). Exhibit 4 - Form of Registration Rights Agreement (included as Exhibit F to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference). Exhibit 5 - Joint Filing Agreement by and between the Reporting Persons (incorporated by reference to Exhibit 5 to the Reporting Persons' Schedule 13D/A as filed with the SEC on May 6, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Foundation Fighting Blindness Retinal Degeneration Fund

Signature:	/s/ Russell Kelley
Name/Title:	Russell Kelley, Managing Director
Date:	05/20/2026

Foundation Fighting Blindness, Inc.

Signature:	/s/ Jason Menzo
Name/Title:	Jason Menzo, Chief Executive Officer
Date:	05/20/2026